PATIENTFORENINGEN BEDSTE SPECIALLÆGER I DK OG EU ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Bankruptcy risk for industry  0.8% 0.8% 0.8% 0.8% 0.8%  
Bankruptcy risk  6.3% 5.7% 5.1% 5.7% 5.2%  
Credit score (0-100)  38 40 42 40 41  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Net sales  0 0 0 0 0  
Gross profit  -57.8 -51.5 -44.4 -41.6 121  
EBITDA  -60.5 -51.6 -44.8 -41.6 -44.8  
EBIT  -60.5 -51.6 -44.8 -41.6 -44.8  
Pre-tax profit (PTP)  -57.7 -52.4 -48.1 -46.2 -50.6  
Net earnings  -57.7 -52.4 -48.1 -29.7 -39.4  
Pre-tax profit without non-rec. items  -57.7 -52.4 -48.1 -46.2 -50.6  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  990 938 889 860 820  
Interest-bearing liabilities  0.0 27.3 93.1 145 348  
Balance sheet total (assets)  1,009 978 996 1,018 1,218  

Net Debt  -18.5 6.4 89.9 136 332  
 
See the entire balance sheet

Volume 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -57.8 -51.5 -44.4 -41.6 121  
Gross profit growth  16.5% 10.9% 13.7% 6.4% 0.0%  
Employees  1 0 0 0 1  
Employee growth %  0.0% -100.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,009 978 996 1,018 1,218  
Balance sheet change%  -8.6% -3.1% 1.8% 2.2% 19.7%  
Added value  -60.5 -51.6 -44.8 -41.6 -44.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  237 31 35 0 175  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -3.0 -4.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  104.6% 100.2% 100.9% 100.0% -37.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -5.4% -5.2% -4.5% -4.1% -4.0%  
ROI %  -5.6% -5.2% -4.6% -4.2% -4.1%  
ROE %  -5.7% -5.4% -5.3% -3.4% -4.7%  

Solidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Equity ratio %  98.1% 95.9% 89.3% 84.5% 67.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  30.6% -12.4% -200.5% -327.3% -742.1%  
Gearing %  0.0% 2.9% 10.5% 16.8% 42.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 9.0% 5.5% 3.9% 2.4%  

Liquidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Quick Ratio  11.0 3.7 1.2 1.0 0.5  
Current Ratio  11.0 3.7 1.2 1.0 0.5  
Cash and cash equivalent  18.5 20.9 3.1 8.5 15.6  

Capital use efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  193.0 109.4 25.9 -3.9 -218.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Net sales / employee  0 0 0 0 0  
Added value / employee  -60 0 0 0 -45  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -60 0 0 0 -45  
EBIT / employee  -60 0 0 0 -45  
Net earnings / employee  -58 0 0 0 -39